Compare Merck & Co., Inc. (MRK) vs abrdn Physical Palladium Shares ETF (PALL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Merck & Co., Inc. vs abrdn Physical Palladium Shares ETF — how do they compare? Merck & Co., Inc. trades at $126.01 (market cap $307.25B), while abrdn Physical Palladium Shares ETF trades at $23.31. The key difference: Merck & Co., Inc. pays a 2.73% dividend while abrdn Physical Palladium Shares ETF pays none, and Merck & Co., Inc. is trading nearer its 52-week high, abrdn Physical Palladium Shares ETF nearer its low. Which is the better fit depends on your goals.
| MRK | PALL | |
|---|---|---|
Market Cap | $307.25B | — |
Sector | Health | Commodities - Metals/Agriculture |
52-Week High | $129.52 | $37.18 |
52-Week Low | $77.60 | $19.96 |
Enterprise Value | $350.66B | — |
Dividend Yield | 2.73% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Merck (MRK) trades at $126.27, down 0.96% on the day, with a neutral technical signal and strong fundamentals including a net income margin of 13.59% and ROE of 18.97%. Recent earnings beats and the acquisition of Terns Pharmaceuticals for approximately $6.7 billion highlight strategic growth initiatives. The stock is supported by a consensus analyst price target of $137.30, indicating potential upside from current levels.
The outlook for Merck is positive, driven by robust profitability, strategic acquisitions, and analyst confidence. Key risks include rising debt levels, with debt-to-asset ratio increasing to 36.06% in 2025, and competitive pressures in the oncology space. Investors should weigh strong cash flow generation against execution risks in integrating recent acquisitions.
PALL (abrdn Physical Palladium Shares ETF) trades at $22.80, up 0.44% with a bearish technical signal from moving averages. Recent news highlights palladium's underperformance versus other precious metals, though some analysts see current price weakness as a buying opportunity. The ETF underwent a 5-for-1 forward share split on May 18, 2026, which adjusted share count without changing the underlying value.
The outlook for PALL hinges on palladium's supply-demand dynamics and industrial usage. While technical indicators suggest near-term pressure, fundamental factors like supply constraints and potential demand recovery could support prices. Key risks include Federal Reserve policy impacts and global economic conditions affecting industrial demand for palladium.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →About abrdn Physical Palladium Shares ETF
PALL is a physically-backed ETF that tracks the spot price of palladium. It holds physical bullion in secure vaults, offering a liquid way to invest in this precious metal primarily used in automotive catalytic converters and electronics.
Read more on PALL →
